Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Download Data

Freeline Therapeutics Holdings Plc Interest Coverage Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending June 30, 2023: 87.48%

Freeline Therapeutics Holdings Plc Interest Coverage Ratio 1 year YoY Change (%) is 87.48% for the Trailing 12 Months (TTM) ending June 30, 2023, a 68.98% change year over year. The interest coverage ratio is a measure of a company's ability to meet its interest payment obligations on its outstanding debt. It is calculated by dividing the company's earnings before interest and taxes (EBIT) by its interest expense. This ratio indicates the extent to which a company's earnings can cover its interest expenses. A higher interest coverage ratio suggests that the company has a greater capacity to make interest payments, indicating lower financial risk. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
  • Freeline Therapeutics Holdings Plc Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was -145.56, a 68.07% change year over year.
  • Freeline Therapeutics Holdings Plc Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2021 was -455.80, a -2.72% change year over year.
  • Freeline Therapeutics Holdings Plc Interest Coverage Ratio for the Trailing 12 Months (TTM) ending September 30, 2020 was -443.73.
NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO Mr. Michael J. Parini J.D.
IPO Date Aug. 7, 2020
Location United Kingdom
Headquarters Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees 152
Sector Healthcare
Industry Biotechnology
Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Similar companies

AVRO

AVROBIO Inc

NA

NA

IMMX

Immix Biopharma Inc

NA

NA

HEPA

Hepion Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email